Found 0 matching trials
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
PHASE2RATIONALE: Biological therapies such as denileukin diftitox may be able to ...
Location
ION/Pharmatech Network
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
PHASE1RATIONALE: White blood cells that have been treated in a laboratory may be ...
Location
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
PHASE2RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protei...
Location
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
PHASE2This study will determine whether treatment with a combination of the drugs...
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
PHASE2The goal of this clinical research study is to find out if the study drug, ...
Location
Tower Cancer Research Foundation
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
PHASE1In the laboratory, we will put a special gene into cancer cells that have b...
Location
Multiple Locations
Denileukine Diftitox for Relapsed ALCL
PHASE2The purpose of this study is to determine is Denileukin diftitox will be sa...
Location
Columbia University Medical Center
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
PHASE2RATIONALE: Biological therapies, such as denileukin diftitox, may be able t...
Location
Jonsson Comprehensive Cancer Center at UCLA
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
PHASE1RATIONALE: Vaccines made from a person's white blood cells mixed with tumor...
Location
Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
PHASE2Adult T-cell leukemia (ATL) is and aggressive characterized by the presence...
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike